GENI - Ticker AI Digest

Genincode PLC 📰 1
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Genincode PLC in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
GENI Data 2025-10-13 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (GENI) 1
GENI 15:22
Genincode PLC
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
GENI 06:01
Genincode PLC
NHS (UCLH) Risk of Ovarian Cancer (ROCA) launch
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GENinCode Plc, a UK-based predictive genetics company, has partnered with the North Central London (NCL) Cancer Alliance and University College London Hospitals NHS Foundation Trust (UCLH) to launch the **Risk of Ovarian Cancer Algorithm (ROCA)** surveillance service. This marks the first NHS implementation of the ROCA <mark style="background-color:yellow">test</mark> outside of a trial setting, offering it as part of UCLHs Familial Cancer Clinic for women at high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene mutations. The service aligns with new NICE guidance, providing an alternative to preventive surgery for women who wish to defer it, such as those planning to have children or avoid early menopause.
The ROCA test uses a proprietary algorithm to calculate individual risk based on factors like CA 125 blood test results, age, menopausal status, and BRCA gene alterations. Studies, including the UKFOCSS and ALDO trials, have shown a **44% reduction in late-stage ovarian cancer detections** with ROCA surveillance, improving treatment outcomes and reducing costs for the NHS. UCLHs initiative empowers eligible women across North Central London by closely monitoring their ovarian cancer risk, mitigating the likelihood of advanced-stage diagnoses.
Key stakeholders, including Professor Adam Rosenthal (UCLH), Ali Malik (NCL Cancer Alliance), and Matthew Walls (GENinCode CEO), highlighted the significance of this milestone in integrating innovative surveillance into clinical practice. GENinCode aims to extend the ROCA test to other NHS trusts in the future. The service is accessible via referrals to the UCLH Familial Cancer Clinic for patients with proven inherited BRCA gene alterations.
**Key Points**
First NHS implementation of ROCA test outside trials.
Targets women with BRCA1/BRCA2 mutations at high risk of ovarian cancer.
Reduces late-stage diagnoses by 44%improves outcomesand saves NHS costs.
Collaboration between GENinCodeUCLHand NCL Cancer Alliance.
Plans to expand to other NHS trusts.
Launch
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 1
GENI 06:01
Genincode PLC
Half-year Report
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of GENinCode Plc Half-Year Report (H1 2025)**
**Overview**
GENinCode Plc, a UK-based predictive genetics company focused on preventing cardiovascular disease (CVD) and ovarian cancer risk, released its unaudited interim results for the six months ended 30 June 2025. The report highlights operational and financial progress, strategic initiatives, and future outlook.
**Operational Highlights**
**Commercial Contracts**Secured the first ROCA commercial contract with the NHS (University College London Hospitals and North Central London Cancer Alliance) for ovarian cancer risk surveillance.
**US Market Growth**Increased sales of LIPID inCode® and CARDIO inCode-Score® in the US, with over 40 clinics onboarded for CVD risk assessment.
**Regulatory Progress**Completed FDA De Novo Supervisory Review for CARDIO inCode-Score®, with agreement on outstanding deficiencies. Expects submission of additional data in Q1 2026.
**European Expansion**Growth in LIPID inCode® usage in Germany, Spain, and Italy, with CARDIO inCode-Score® pilots in Spain.
**Presentations**Showcased research at major cardiology conferences, emphasizing genetic modulation of cholesterol risk.
**Financial Highlights**
**Revenue Growth**First-half revenues increased by 15% to £1.60 million (H1 2024: £1.39 million), driven by growth in the UK, EU, and US.
**Fundraising**Successfully raised £3.7 million (gross £4.1 million) in March 2025 to support expansion.
**Adjusted EBITDA Loss**£2.07 million (H1 2024: £2.05 million), excluding unrealized forex loss.
**Cash Reserves**Increased to £2.44 million at 30 June 2025 (31 Dec 2024: £1.11 million).
**Outlook**
**Revenue Expectations**Full-year revenue revised to £3.3 million (lower than expected due to NHS restructuring and FDA delays).
**Strategic Focus**Expanding LIPID inCode® and CARDIO inCode-Score® in the US, EU, and UK.
**Regulatory Milestones**Aiming for FDA submission of CARDIO inCode-Score® in Q1 2026.
**Partnerships**Expanding collaborations in Germany, Spain, and with the NHS for ROCA ovarian cancer testing.
**CEO Statement**
Matthew Walls, CEO, emphasized increased revenues across core markets and progress in US regulatory pathways. However, NHS funding uncertainty and FDA delays impacted full-year revenue expectations. The company remains focused on commercial expansion, cost control, and strengthening its market presence.
**Financial Review**
**Revenue Breakdown**Spain remains the largest market, with 14% growth. UK sales increased to £383k, boosted by ROCA test sales.
**Gross Profit**Improved to £849k (H1 2024: £730k), with margins at 53.0%.
**Administrative Expenses**Slightly higher at £2.92 million due to inflationary pressures.
**Cash Flow**Operating cash outflow decreased to £3.22 million (H1 2024: £3.39 million).
**Conclusion**
GENinCode Plc demonstrated resilience in H1 2025, with revenue growth and strategic advancements despite regulatory and NHS-related challenges. The company is poised for further expansion, supported by its innovative genetic testing solutions and ongoing partnerships.
Here is the HTML table code comparing the financials and debt year on year for GENinCode Plc:
Financial MetricH1 2025 (£'000)H1 2024 (£'000)Change (£'000)Change (%)
Revenue1,6021,38921315%
Gross Profit84973011916%
Adjusted EBITDA Loss(2,069)(2,054)(15)1%
Operating Loss(2,970)(2,475)(495)20%
Total Comprehensive Loss(2,463)(2,361)(102)4%
Cash Reserves2,4382,915(477)-16%
Trade and Other Receivables1,22980542453%
Trade and Other Payables1,3601,378(18)-1%
Lease Liability (Non-Current)191180116%

Key Observations:

  • Revenue increased by 15% year-on-year, driven by growth in UK, EU, and US markets.
  • Gross profit margin improved slightly to 53.0% from 52.6% in H1 2024.
  • Adjusted EBITDA loss remained relatively stable, increasing only slightly by £15k.
  • Cash reserves decreased by 16% due to operating cash outflows, partially offset by a successful fundraising in March 2025.
  • Trade and other receivables increased significantly, reflecting higher revenues and debtor balances in Spain and the US.
This table provides a clear comparison of key financial metrics between H1 2025 and H1 2024, highlighting the changes in both absolute and percentage terms. The observations summarize the main trends and changes in the company's financials.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 1
GENI 09:43
Genincode PLC
Stmnt re Share Price Movement
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GENinCode Plc, a UK-based predictive genetics company focused on preventing cardiovascular disease (CVD) and ovarian cancer (OC), issued a statement on September 17, 2025, addressing recent share price movements. The company stated it was unaware of any specific reasons for the sudden price fluctuations but reaffirmed its belief that the shares remain undervalued. GENinCode reconfirmed its trading and operational position from the August 26, 2025 update, highlighting ongoing progress in FDA De Novo discussions and efforts to address remaining deficiencies. Collaboration talks with a major distributor for potential U.S. and EU <mark style="background-color:yellow">test</mark> distribution are advancing. The company plans to provide further updates during its interim results announcement on September 30, 2025.
GENinCode specializes in genetic risk assessment for CVD, the leading global cause of death, and OC, with its ROCA test being a globally leading surveillance tool for early OC detection, particularly for BRCA gene mutation carriers. The ROCA test has received NICE guideline recommendation for OC surveillance. The company operates in the UK, Europe, and the U.S., leveraging clinical algorithms and AI bioinformatics to enhance patient risk assessment and preventive care.
Speculation
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 2
GENI 15:22
Genincode PLC
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
GENI 16:59
Genincode PLC
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 5
GENI 15:22
Genincode PLC
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
GENI 06:01
Genincode PLC
Half-year Report
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of GENinCode Plc Half-Year Report (H1 2025)**
**Overview**
GENinCode Plc, a UK-based predictive genetics company focused on preventing cardiovascular disease (CVD) and ovarian cancer risk, released its unaudited interim results for the six months ended 30 June 2025. The report highlights operational and financial progress, strategic initiatives, and future outlook.
**Operational Highlights**
**Commercial Contracts**Secured the first ROCA commercial contract with the NHS (University College London Hospitals and North Central London Cancer Alliance) for ovarian cancer risk surveillance.
**US Market Growth**Increased sales of LIPID inCode® and CARDIO inCode-Score® in the US, with over 40 clinics onboarded for CVD risk assessment.
**Regulatory Progress**Completed FDA De Novo Supervisory Review for CARDIO inCode-Score®, with agreement on outstanding deficiencies. Expects submission of additional data in Q1 2026.
**European Expansion**Growth in LIPID inCode® usage in Germany, Spain, and Italy, with CARDIO inCode-Score® pilots in Spain.
**Presentations**Showcased research at major cardiology conferences, emphasizing genetic modulation of cholesterol risk.
**Financial Highlights**
**Revenue Growth**First-half revenues increased by 15% to £1.60 million (H1 2024: £1.39 million), driven by growth in the UK, EU, and US.
**Fundraising**Successfully raised £3.7 million (gross £4.1 million) in March 2025 to support expansion.
**Adjusted EBITDA Loss**£2.07 million (H1 2024: £2.05 million), excluding unrealized forex loss.
**Cash Reserves**Increased to £2.44 million at 30 June 2025 (31 Dec 2024: £1.11 million).
**Outlook**
**Revenue Expectations**Full-year revenue revised to £3.3 million (lower than expected due to NHS restructuring and FDA delays).
**Strategic Focus**Expanding LIPID inCode® and CARDIO inCode-Score® in the US, EU, and UK.
**Regulatory Milestones**Aiming for FDA submission of CARDIO inCode-Score® in Q1 2026.
**Partnerships**Expanding collaborations in Germany, Spain, and with the NHS for ROCA ovarian cancer testing.
**CEO Statement**
Matthew Walls, CEO, emphasized increased revenues across core markets and progress in US regulatory pathways. However, NHS funding uncertainty and FDA delays impacted full-year revenue expectations. The company remains focused on commercial expansion, cost control, and strengthening its market presence.
**Financial Review**
**Revenue Breakdown**Spain remains the largest market, with 14% growth. UK sales increased to £383k, boosted by ROCA test sales.
**Gross Profit**Improved to £849k (H1 2024: £730k), with margins at 53.0%.
**Administrative Expenses**Slightly higher at £2.92 million due to inflationary pressures.
**Cash Flow**Operating cash outflow decreased to £3.22 million (H1 2024: £3.39 million).
**Conclusion**
GENinCode Plc demonstrated resilience in H1 2025, with revenue growth and strategic advancements despite regulatory and NHS-related challenges. The company is poised for further expansion, supported by its innovative genetic testing solutions and ongoing partnerships.
Here is the HTML table code comparing the financials and debt year on year for GENinCode Plc:
Financial MetricH1 2025 (£'000)H1 2024 (£'000)Change (£'000)Change (%)
Revenue1,6021,38921315%
Gross Profit84973011916%
Adjusted EBITDA Loss(2,069)(2,054)(15)1%
Operating Loss(2,970)(2,475)(495)20%
Total Comprehensive Loss(2,463)(2,361)(102)4%
Cash Reserves2,4382,915(477)-16%
Trade and Other Receivables1,22980542453%
Trade and Other Payables1,3601,378(18)-1%
Lease Liability (Non-Current)191180116%

Key Observations:

  • Revenue increased by 15% year-on-year, driven by growth in UK, EU, and US markets.
  • Gross profit margin improved slightly to 53.0% from 52.6% in H1 2024.
  • Adjusted EBITDA loss remained relatively stable, increasing only slightly by £15k.
  • Cash reserves decreased by 16% due to operating cash outflows, partially offset by a successful fundraising in March 2025.
  • Trade and other receivables increased significantly, reflecting higher revenues and debtor balances in Spain and the US.
This table provides a clear comparison of key financial metrics between H1 2025 and H1 2024, highlighting the changes in both absolute and percentage terms. The observations summarize the main trends and changes in the company's financials.
GENI 06:01
Genincode PLC
NHS (UCLH) Risk of Ovarian Cancer (ROCA) launch
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GENinCode Plc, a UK-based predictive genetics company, has partnered with the North Central London (NCL) Cancer Alliance and University College London Hospitals NHS Foundation Trust (UCLH) to launch the **Risk of Ovarian Cancer Algorithm (ROCA)** surveillance service. This marks the first NHS implementation of the ROCA <mark style="background-color:yellow">test</mark> outside of a trial setting, offering it as part of UCLHs Familial Cancer Clinic for women at high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene mutations. The service aligns with new NICE guidance, providing an alternative to preventive surgery for women who wish to defer it, such as those planning to have children or avoid early menopause.
The ROCA test uses a proprietary algorithm to calculate individual risk based on factors like CA 125 blood test results, age, menopausal status, and BRCA gene alterations. Studies, including the UKFOCSS and ALDO trials, have shown a **44% reduction in late-stage ovarian cancer detections** with ROCA surveillance, improving treatment outcomes and reducing costs for the NHS. UCLHs initiative empowers eligible women across North Central London by closely monitoring their ovarian cancer risk, mitigating the likelihood of advanced-stage diagnoses.
Key stakeholders, including Professor Adam Rosenthal (UCLH), Ali Malik (NCL Cancer Alliance), and Matthew Walls (GENinCode CEO), highlighted the significance of this milestone in integrating innovative surveillance into clinical practice. GENinCode aims to extend the ROCA test to other NHS trusts in the future. The service is accessible via referrals to the UCLH Familial Cancer Clinic for patients with proven inherited BRCA gene alterations.
**Key Points**
First NHS implementation of ROCA test outside trials.
Targets women with BRCA1/BRCA2 mutations at high risk of ovarian cancer.
Reduces late-stage diagnoses by 44%improves outcomesand saves NHS costs.
Collaboration between GENinCodeUCLHand NCL Cancer Alliance.
Plans to expand to other NHS trusts.
Launch
GENI 16:59
Genincode PLC
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
GENI 09:43
Genincode PLC
Stmnt re Share Price Movement
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GENinCode Plc, a UK-based predictive genetics company focused on preventing cardiovascular disease (CVD) and ovarian cancer (OC), issued a statement on September 17, 2025, addressing recent share price movements. The company stated it was unaware of any specific reasons for the sudden price fluctuations but reaffirmed its belief that the shares remain undervalued. GENinCode reconfirmed its trading and operational position from the August 26, 2025 update, highlighting ongoing progress in FDA De Novo discussions and efforts to address remaining deficiencies. Collaboration talks with a major distributor for potential U.S. and EU <mark style="background-color:yellow">test</mark> distribution are advancing. The company plans to provide further updates during its interim results announcement on September 30, 2025.
GENinCode specializes in genetic risk assessment for CVD, the leading global cause of death, and OC, with its ROCA test being a globally leading surveillance tool for early OC detection, particularly for BRCA gene mutation carriers. The ROCA test has received NICE guideline recommendation for OC surveillance. The company operates in the UK, Europe, and the U.S., leveraging clinical algorithms and AI bioinformatics to enhance patient risk assessment and preventive care.
Speculation

Today's AI

Today's AI Starts With News

1 live catalyst is opening Today’s AI for GENI.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2025-10-13 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
Genincode PLC has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
Single-Ticker Today's AI
GENI signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for Genincode PLC. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full GENI Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for GENI on 2025-10-13.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
7.6M
Enterprise Value
35.4M
Public Float
20.6
Broker Target
7.5
Shares Out
725.0M
Long Interest
100
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
None
Market
None
Sector
Gas, Water and Multi-utilities
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for GENI.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2025-10-13 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
Genincode PLC has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2025-09-23
Net Debt
-876.0K
Cash
1.1M
EPS
-0.02
Net Income
-4.4M
Revenue
2.7M
Enterprise Value
35.4M
Trailing PE
-
Forward PE
-
Price Sales TTM
2.61
Price Book MRQ
2.8587
EV Revenue
1.8191
EV EBITDA
-3.1541
Financial Forecastist

Improving financial engine

Revenue is accelerating +32.4% against the prior comparable period. Net margin is expanding by 105.5 pts. Net debt is building +2.8%.

Revenue +32.4% Net Income -15.7% FCF +5.9% Current Ratio 2.80x Forward Rev 0
Improving
Quarter Revenue
1.6M
+32.4%
vs prior comparable quarter
Net Margin
-185.0%
+105.5 pts
profitability pulse
Free Cash Flow
-3.2M
+5.9%
cash conversion
Net Debt / EBITDA
1.0x
+2.8%
lower is cleaner
Revenue Engine

Latest quarter printed 1.6M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at -3.0M and the margin profile is broadening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 2.4M while net debt is -2.2M. The leverage stack is moving the wrong way.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2023
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q2 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2025
Consensus
3.1M
Revenue Path
-0.02
EPS / Earnings
Growth cue +0.3%
FY 2026
Consensus
4.7M
Revenue Path
-0.01
EPS / Earnings
Growth cue +0.7%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q2 2025 1.6M -3.0M -3.2M -2.2M
Q4 2024 1.3M -2.0M -1.8M -876.0K
Q2 2024 1.4M -2.4M -3.4M -2.7M
Q1 2024 694.5K -1.2M -1.7M -2.9M
Q4 2023 1.2M -3.5M -3.0M -2.2M
Q3 2023 605.0K -1.8M -1.5M -2.3M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2024 2.7M -4.4M -4.7M -5.2M
FY 2023 2.2M -7.0M -6.6M -7.5M
FY 2022 1.4M -5.6M -5.6M -4.6M
FY 2021 1.2M -4.1M -4.1M -3.2M
FY 2020 960.8K -1.2M -1.0M -1.1M

Structure DNA

Market Structure DNA

Balanced Structure profile with trend broken

Price is 6.5% through the 52-week range, +7.5% vs 50DMA and -41.2% vs 200DMA. 47.6% of the register is locked by institutions and insiders, leaving 52.4% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend broken Institutional gravity Moderate income rhythm As Of 2026-04-19
Balanced Structure
Structure Score
44.6 / 100
Balanced Structure
Trend Stack
+7.5% / -41.2%
vs 50DMA / 200DMA
52W Position
6.5%
auction position inside the yearly range
Ownership Lock
47.6%
24.6% institutions | 23.1% insiders
Pressure Pocket
52.4% free float
Vendor short-float fields were not supplied
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 1.20 with the stock +7.5% vs 50DMA and -41.2% vs 200DMA. The tape is sitting 6.5% through the 52-week range, which frames the regime as trend broken.

Ownership Register

Institutions hold about 24.6% and insiders about 23.1%, locking roughly 47.6% of the register and leaving 52.4% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
1.20
derived from market cap / shares
52W High
5.50
upper auction edge
52W Low
0.90
lower auction edge
Beta
0.56
volatility character
Shares Out
725.0M
fully diluted count
Shares Float
151.1M
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
43.1006
Institutions As Of
2026-05-08
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
4
Sale TR1
6
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for GENI, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2025-10-13 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
Genincode PLC has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
GENI Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-10-13 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast -25.83%
RSI Gauge
Price Change
AI Forecast